DOI: http://dx.doi.org/10.18203/2349-2902.isj20211828

Gastrointestinal stromal tumours: a clinico-pathological study

Nuvvula Satwik, Joseph Francis, Natasha Mathias

Abstract


Background: The aim was to evaluate the clinical presentation, histopathological findings and immunohistochemistry in gastrointestinal stromal tumour (GIST) to better understand the disease.

Methods: Patients admitted and suspected to have GISTs in the Departments of General Surgery and Oncology, Yenepoya Medical College from the period of October 2016 to October 2018 were included in the study.

Results: From October 2016 to October 2018, 10 patients had been diagnosed with gastro-intestinal stromal tumour in Yenepoya Medical College. Out of the 10 patients 7 were males and 3 females. The age distribution showed that more than 70% of the cases were above the age of 55 years. Stomach was the most common site of GIST. The most common histopathological type was spindle cell type of GIST, and 70% of the GISTs came positive for CD117.

Conclusions: To conclude, Gastro intestinal stromal tumours are a rare entity. In this study conducted in a tertiary centre only ten cases were reported in a span of two years of the study period. Further analysis of age and gender distribution, histopathological and immunohistochemistry of these tumours suggested that in majority, age group was found to be above 55 years, with male preponderance. Commonest site was stomach (40%) followed by jejunum. Common histopathological finding was found to be spindle cell variant. 70% cases were CD117 positive with more than 5 mitotic figures/50 high power fields.

 


Keywords


Gastrointestinal autonomic nerve tumours, Gastrointestinal stromal tumours, Immunohistochemistry, Interstitial cells of Cajal, Platelet-derived growth factor receptor alpha, Positron emission tomography (PET) scanning using fluorodeoxyglucose

Full Text:

PDF

References


Crosby JA, Catton CN, Davis A, Couture J, O’Sullivan B, Kandel R, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol. 2001;8(1):50-9.

DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumours: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51-8.

Nishida T, Hirota S. Biological and clinical review of stromal tumours in the gastrointestinal tract. Histol Histopathol. 2000;15(4):1293-301.

Miettinen M, Lasota J. Gastrointestinal stromal tumours- definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438(1):1-12.

Nilsson B, Bümming P, Meis‐Kindblom JM, Odén A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumours: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era- a population-based study in western Sweden. Cancer. 2005;103(4):821-9.

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577-80.

Savage DG, Antman KH. Imatinib mesylate- a new oral targeted therapy. N Engl J Med. 2002;346(9):683-93.

Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001;61(22):8118-21.

Tian Q, Frierson HF, Jr, Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumours. Am J Pathol. 1999;154(6):1643-7.

Ward SM, Burns AJ, Torihashi S, Sanders KM. Mutation of the protooncogene c-kit blocks development of interstitial cells and electrical rhythmicity in murine intestine. J Physiol. 1994;480(pt 1):91-7.

Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20(6):1692-703.

De Giorgi U, Verweij J. Imatinib and gastrointestinal stromal tumours: where do we go from here? Mol Cancer Ther. 2005;4(3):495-501.

Heinrich MC, Corless CL, Duensing A. PDGFRA activating mutations in gastrointestinal stromal tumours. Science. 2003;299(5607):708-10.

Agaram NP, Laquaglia MP, Ustun B. Molecular characterization of pediatric gastrointestinal stromal tumours. Clin Cancer Res. 2008;14(10):3204-15.

Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000;13:1134.

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577-80.

Fletcher CD, Berman JJ, Corless C. Diagnosis of gastrointestinal stromal tumours: a consensus approach. Int J Surg Pathol 2002;10:81.

Sakurai S, Fukasawa T, Chong JM, Tanaka A, Fukayama M. C-kit gene abnormalities in gastrointestinal stromal tumours (tumours of interstitial cells of Cajal. Japan J Cancer Res. 1999;90:1321.

Wang L, Vargas H, French SW. Cellular origin of gastrointestinal stromal tumours: a study of 27 cases. Arch Pathol Lab Med. 2000;124:1471.

Sircar K, Hewlett BR, Huizinga JD. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumours. Am J Surg Pathol. 1999;23:377.

Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol. 2001;54:96.

Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. PDGFRA mutations in gastrointestinal stromal tumours: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23:5357.

Yamamoto H, Oda Y, Kawaguchi K, Nakamura N, Takahira T, Tamiya S, et al. c-kit and PDGFRA mutations in extragastrointestinal stromal tumour (gastrointestinal stromal tumour of the soft tissue). Am J Surg Pathol. 2004;28:479.

Miettinen M, Monihan JM, Sarlomo-Rikala M, Kovatich AJ, Carr NJ, Emory TS, et al. Gastrointestinal stromal tumours/smooth muscle tumours (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol. 1999;23:1109.

Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, et al. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012;3:1566.

Liegl B, Hornick JL, Lazar AJ. Contemporary pathology of gastrointestinal stromal tumours. Hematol Oncol Clin North Am. 2009;23:49.

Maynard MA, Marino-Enriquez A, Fletcher JA, Dorfman DM, Raut CP, Yassa L, et al. Thyroid hormone inactivation in gastrointestinal stromal tumours. N Engl J Med. 2014;370:1327.

Sobin LH, Lasota J. Gastrointestinal stromal tumors presenting as omental masses-a clinicopathologic analysis of 95 cases. Am J Surg Pathol. 2009;33(9):1267-75.

Rubin BP, Fletcher JA, Fletcher CD. Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumours. Int J Surg Pathol. 2000;8:5.

Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol. 2001;54:96.

Novelli M, Rossi S, Rodriguez‐Justo M, Taniere P, Seddon B, Toffolatti L, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology. 2010;57:259.

Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumours: a study of 1840 cases. Am J Surg Pathol. 2009;33:1401.

Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumours, including unusual subtypes. Am J Surg Pathol. 2009;33:437.

West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumours irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165:107.

Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumours: proof of concept and therapeutic implications. Am J Surg Pathol. 2004;28:889

Miettinen M, Fletcher CDM, Kindblom LG, Tsui WMS. Mesenchymal tumours of the stomach, small intestine, colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO classification of tumours of the digestive system. 4th edn. Lyon: IARC; 2010:74-9,115-116,181-2.

Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005;100(1):162-8.

Ma GL, Murphy JD, Martinez ME, Sicklick JK. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Prevent Biomark. 2015;24(1):298-302.

Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001;61(22):8118-21.